Welcome to this episode! We Talked to Michaels Quirmbach CEO of CordenPharma and discussed thir ambitious plans and recent strategic moves. Michael will share insights on their record-breaking €1 billion investment over the next three years to expand peptide manufacturing across Europe and the US, including a major greenfield site outside Basel, Switzerland. We'll explore what motivated this huge push, why Basel was chosen, and what sets CordenPharma apart in the competitive GLP-1 space.

Plus, we'll get a sneak peek into other platform expansions and updates on CordenPharma's sustainability and ESG initiatives. Stay tuned!